Rebranding of Rejuveron Life Sciences AG as Centenara Labs AG with latest clinical updates

• Aktionäre genehmigen names and rebranding as Centenara Labs AG (“Centenara”)
• The rebranding is a light of another strategic initiative to start the treatment in regenerative meditation and for a different condition of the therapy
• The second part of treatment with EA-2353 can cause blindness in retinitis pigmentosa

SCHLIEREN, Switzerland, September 19, 2024 (GLOBE NEWSWIRE) — Die Centenara Labs AG (kurz „One hundred years“ or that “Entrepreneurs“) (vormals Rejuveron Life Sciences AG), in Zurich we are prepared to accept Biotechnologies with the help of the therapy for healthy changes, but we are willing to take action in the new general regulations („)AGV“) On August 23, 2024, the naming of Centenara Labs AG was generated. With the strategic naming and the entire general rebranding, the difference between the departments on the market is resolved and the attention for the departments is put on the waiting list for a century.

The new company name that explores Centenara’s involvement means that your functioning function, your healthy and healthy fitness, your healthy lifestyle will improve in a healthier way and last longer quality products that hang in the kitchen with hundertjährigen Menschen (engl. Centenarians) is such a weighty discussion topic. During the process and the new business operations, which are influenced by the fundamental changes, the turn of the century will expand – but man will no longer live longer, otherwise at an older age bensqualität beibehalten.

“A newcomer like Centenara is a smarter and more orientated writer, in itself with a strategic vision and more meaningful than a clean naming: There is a tension that stands in the way of the treatment of the treatment. Regenerative medicine and altersbedingter Erkrankungen entwickelt”, says Aksana Labokha, CEO von Centenara. „One of the most recent versions of this picture is our own entity and has a biotechnology sector during the production of factories for a longer life. There is no successful business if Centenara no longer has a strategic vision of the market presence and partnerships in the pharmaceutical industry, which means that our investments in a pipeline of high-growth companies are no longer as great Alternative strong.”

If you are innovative, you can be involved in the development and development of the most common examinations in ophthalmology and the treatment of new art therapy for a treatment of a treatment and a treatment, which lasts longer and longer. For the purpose of the rebranding, Centenara invites members and other interests to view the refreshed website and the new company promotion under https://centenara.com.

Clinical Update on EA-2353: Treatment of Retinitis pigmentosa

I am working on the rebranding improvement of the Centenara update for an update of the main programs for EA-2353 for the treatment of retinitis pigmentosa (kurz “RP“), which encourages a progressive net degeneration with delight in Sehfähigkeit. EA-2353 is an endogenous stem cell that has no molecular action, the “sleeping” retinal stem and vorläufercellen zur Erhaltung or Restoring of Sehvermögens animates. RP is a fixed value in the mains supply, which is free, and most patients get an alternative of 40 years full of blind sins. A first clinical study of phase I/IIa in humans could occur with many problems, while the EA-2353 is safe and digestible. The exploratory analyses that have been carried out in a positive way relate to the development of the time, the net development and the structure of the net development in the completed situation. The second generation is the treatment, which this ergebnisse an emerging treatment in health care has undergone, was a therapy with Schwerpunkt to the Stammzellen treatment.

The treatment of most patients with RP exploration EA-2353, a new treatment, is being looked at, which allows a treatment that is performed in the different genetically modified way of RP. The US-American Drug Authority FDA granted EA-2353 the status as Orphan Drug in May 2021.

In a hundred years

Centenara is a biotechnology company with clinical development programs for therapy for the treatment of alternative therapies. Seine in der Erforschung und Entwicklung von Wirkstoffen foutahrene Belegschaft kunstügtüber vertiefte Kenntnisse der Altersbiologie anyway various new solutions in the biopharmaceutical F+E, with deren Hilfe sie a new generation of Arzneimitteln vorantreibt, thanks to the people who will live alternately and longer.

All Centenara concentrate programs are performed in a simple way in the field of prevention, repair or repair of the main brands on the alternatives. So if you are using a therapeutic pipeline, it is important that you get a clinical treatment. The active portfolio is in the modal phase, the lung stage and the alternative possibilities have been developed and includes a revolutionary new molecular analysis of regeneration endogenous strains, which are being investigated in a phase I/IIa study in the US and patients with RP.

As the current product pipeline expands to include therapies for the treatment of macular degeneration in the clinical phase, new therapies for other changes in the disease in the treatment of fibrosis and muscle tissue, a telomere program with the repair process and the repair of repair or recovery will take place zten Telomeres as well as Program, which will eliminate neurodegenerative and cognitive disorders.

Centenara Wurde 2019 durch unternehmerisch Denken Wissenschaftler Matthias Steger und die most targeted Anleger Christian Angermayer gemeinsam gegründet.

Aksana Labokha, CEO [email protected]